Poseida Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Poseida Therapeutics

08/11/2021 22:12

* Poseida Therapeutics Inc  PSTX.OQ   PSTX.O  is expected
to show no change in quarterly revenue when it reports 
results on November 10 (estimated). 
​* Refinitiv's mean analyst estimate for Poseida Therapeutics
Inc is for a loss of 74 cents per share. For the same quarter
last year, the company reported a loss of 63 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $20​, about 65.5% above​ its last closing
price of $6.91. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.63       -0.63      -0.74     Missed  -17.5
 Mar. 31 2021  -0.64       -0.63      -0.62     Beat    2.4
 Dec. 31 2020  -0.69       -0.69      -0.58     Beat    15.5​
 Sep. 30 2020  -0.55       -0.55      -0.63     Missed  -14.5
 ​​Jun.        -1.48       -1.48      -2.28     Missed  -54.1
 30 2020                                                
                                                        ​
 This summary was machine generated November 8 at 22:12 GMT.  All
figures in US dollars unless otherwise stated